Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisProfile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisAn update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosisPharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.Newer multiple sclerosis drugs and disability scores-are key data analyses missing?Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyEffects of Specialty Pharmacy Care on Health Outcomes in Multiple SclerosisPeginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.Multiple sclerosis: Pathology, diagnosis and treatments.The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis.Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosisPharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisPeginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEResearchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisAnalysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patientsCOMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjectsManagement Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.S1P signaling: new therapies and opportunities.Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.PEGylated IFNβ-1a in the treatment of multiple sclerosis.Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.
P2860
Q24187126-0D38573F-87E2-49EF-BB0A-AC7F872C4B99Q26773978-5C2DA71F-62E4-4492-B239-0ECD7F37A0A9Q26777329-69CAA223-A7AB-4CF0-864E-6D8FF546A70BQ26777686-EE9AA8B5-0504-41EF-BADB-B19E5CAF3A77Q26852672-0EA98BC1-CC10-443F-AB3F-DABDB14C45B4Q27000269-7847DF8D-4DD9-4C95-A9BD-89E957418B5EQ28076879-607DF0B1-3A5F-4DB2-8F6A-A0125230E8D8Q30379738-B1B3F699-59AD-4626-8E15-3C1036383BB0Q30839407-30AE030C-8B79-42F2-82B3-2222288AACAEQ30943783-3FC993D9-8332-4DF6-88A5-19003C307516Q31123447-577D395C-783F-4E9A-B8C6-8061ED230319Q33572798-78C20985-D071-445A-9F36-7FB45D2B00FBQ33589958-0349511B-CB9C-4875-B333-0EF722CCBB63Q33745006-68BF9893-D591-4026-937D-774D0E3D16B1Q33810082-3522552B-5BEF-4ED1-A0EC-FB65DD110965Q34355672-E0C5CD76-94C9-4BA1-AB0F-BCC26194A88EQ35004153-DEB49810-7090-423D-B033-0CF27A0105E9Q35030123-AFA9B313-47BD-40B0-89E7-FD639FCD5F7CQ35135977-872CDB1D-9F15-4E2A-8E3E-73DBFC00047BQ35651621-27F88E53-D2F4-4BEA-B28A-78B45B85CF3FQ35882269-949D7E41-66C7-42CF-8FB8-42CB35F0D4A6Q36065033-91D77FCC-42E7-4AFB-88CD-81FD50E17CD2Q36275984-4A4E39F3-1A3A-402C-945D-D27A4F941C92Q36484448-B053951F-B28A-4C4E-A536-061302A9DE60Q37112468-74F1626F-3B9F-465B-8D3F-3D5E57CE1DD6Q37149447-629BF093-F8AA-4A56-B6AD-C33D71953F61Q37174681-FA21E333-C379-4FF7-B115-598BEBF6725AQ37231085-02D3436C-5D96-4B41-AE1D-F3F895476EADQ37422818-EE3D62C6-075F-40AC-9823-97494912CBB3Q37514237-8536DCF6-2E6F-4445-A5A8-B754F773C565Q38314882-2A24EAF1-5BA9-4966-BD22-6C29634E7552Q38315918-6F67CE44-94B0-42F8-A3DE-B16EE25A0A66Q38315992-2573CAB0-339D-428F-9EF6-41E1413C58BBQ38349772-7B9EC780-08E8-443D-B44A-CBBDA2BA338BQ38375671-71D5516E-2F69-47F0-B218-5CDFC726166CQ38379249-BA5FB432-5F1B-4C00-81D9-EC9C9461F058Q38444543-49D962CA-DEC9-4BEE-BB72-701F70087A69Q38513495-E04FF1EE-9E03-4AFF-8984-23F7ABDBB796Q38611027-F9DBEBA4-F108-4A77-A96A-9061F952F410Q38678739-9A71C0A2-6BFD-4794-B481-F2E01479AD85
P2860
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@ast
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@en
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@nl
type
label
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@ast
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@en
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@nl
prefLabel
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@ast
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@en
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@nl
P2093
P50
P1433
P1476
Pegylated interferon β-1a for ...... , phase 3, double-blind study.
@en
P2093
ADVANCE Study Investigators
Aaron Deykin
Alexey Boyko
Ali Seddighzadeh
Douglas L Arnold
Jean Pelletier
Serena Hung
Shifang Liu
P304
P356
10.1016/S1474-4422(14)70068-7
P577
2014-04-30T00:00:00Z